Market Research Logo

GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review

GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
HighlightsGW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing products for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy syndrome, glioma, schizophrenia, autism among others. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc Key Recent Developments

Nov 27,2018: GW Pharmaceuticals announces fiscal fourth quarter and year-end 2018 financial results and operational progress
Nov 01,2018: EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
Oct 22,2018: Food and Drug Administration (FDA) Approval of GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences' EPIDIOLEX (cannabidiol) CV Marks First Drug Approval and Scheduling Decision Supported by Analgesic Solutions' MADDERS System
Aug 28,2018: GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology
Aug 07,2018: GW Pharmaceuticals reports fiscal third quarter 2018 financial results and operational progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
GW Pharmaceuticals Plc - Key Facts
GW Pharmaceuticals Plc - Key Employees
GW Pharmaceuticals Plc - Key Employee Biographies
GW Pharmaceuticals Plc - Major Products and Services
GW Pharmaceuticals Plc - History
GW Pharmaceuticals Plc - Company Statement
GW Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
GW Pharmaceuticals Plc - Business Description
Geographical Segment: Asia/Other
Performance
Geographical Segment: Canada
Performance
Geographical Segment: Europe (Excluding the UK)
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
GW Pharmaceuticals Plc - Corporate Strategy
GW Pharmaceuticals Plc - SWOT Analysis
SWOT Analysis - Overview
GW Pharmaceuticals Plc - Strengths
GW Pharmaceuticals Plc - Weaknesses
GW Pharmaceuticals Plc - Opportunities
GW Pharmaceuticals Plc - Threats
GW Pharmaceuticals Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
GW Pharmaceuticals Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 01, 2018: EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
Oct 22, 2018: Food and Drug Administration (FDA) Approval of GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences' EPIDIOLEX (cannabidiol) CV Marks First Drug Approval and Scheduling Decision Supported by Analgesic Solutions' MADDERS System
Aug 07, 2018: GW Pharmaceuticals reports fiscal third quarter 2018 financial results and operational progress
Aug 02, 2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
GW Pharmaceuticals Plc, Key Facts
GW Pharmaceuticals Plc, Key Employees
GW Pharmaceuticals Plc, Key Employee Biographies
GW Pharmaceuticals Plc, Major Products and Services
GW Pharmaceuticals Plc, History
GW Pharmaceuticals Plc, Other Locations
GW Pharmaceuticals Plc, Subsidiaries
GW Pharmaceuticals Plc, Key Competitors
GW Pharmaceuticals Plc, Ratios based on current share price
GW Pharmaceuticals Plc, Annual Ratios
GW Pharmaceuticals Plc, Annual Ratios (Cont...1)
GW Pharmaceuticals Plc, Annual Ratios (Cont...2)
GW Pharmaceuticals Plc, Interim Ratios
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
GW Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
GW Pharmaceuticals Plc, Performance Chart (2013 - 2017)
GW Pharmaceuticals Plc, Ratio Charts
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report